Immunotherapy shrinks tumors in genetic subtype of colon cancer
NCT ID NCT06428487
First seen Apr 28, 2026 · Last updated May 16, 2026 · Updated 4 times
Summary
This study tested an immunotherapy drug called prolgolimab in 30 people with stage II-III colorectal cancer that has a specific genetic feature (MSI/dMMR). Participants received the drug for 6 months before surgery. The main goal was to see if the cancer completely disappeared by the time of surgery. This approach aims to control the disease and improve outcomes, but ongoing monitoring is needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
N.N. Blokhin NMRCO
Moscow, Russia
Conditions
Explore the condition pages connected to this study.